~~<i id='96405D9AEA'><strike id='96405D9AEA'><tt id='96405D9AEA'><pre id='96405D9AEA'></pre></tt></strike></i>~~

Home» knowledge» explore

explore

author：comprehensive 2025-10-04 10:13:02 Page View：294

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The new shift in health care is toward less care
Next article： Activists slam private health insurers over coverage restrictions

explore

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

AdobeLastweek,theWashingtonPostpublishedanop-edbyformerCDCDirectorTomFriedentitled,“It’stheworld’sle

Affirmative action in medical school literally saved lives

AdobeThepastseveralmonthshavebeengrimforhealthintheU.S.InDecember,theCentersforDiseaseControlandPrev

PhRMA lawsuit over Medicare drug price negotiation tossed

APStockWASHINGTON—AfederaldistrictjudgeonMondaygrantedtheBidenadministration’srequesttodismissalawsu